导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 22.43% | 317/4773 |
| 近一周 | 0.96% | 544/5465 |
| 近一月 | -4.63% | 3366/5421 |
| 近一季 | -9.83% | 3656/5231 |
| 近半年 | 19.44% | 225/4920 |
| 近一年 | 24.26% | 347/4394 |
| 近两年 | 146.68% | 265/2954 |
| 近三年 | 104.22% | 149/2253 |
| 成立以来 | 192.56% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.01% 4201/4961 |
74.60% 219/5312 |
- - |
- - |
| 2025 | 39.34% 829/4813 |
2.85% 1248/3635 |
-0.20% 2840/4076 |
44.73% 617/4524 |
-6.21% 3680/4813 |
| 2024 | 20.63% 452/3463 |
-6.39% 2050/2808 |
0.01% 660/3014 |
14.85% 1893/3129 |
12.17% 183/3463 |
| 2023 | 3.57% 273/2656 |
23.41% 113/2280 |
-5.68% 1516/2385 |
-9.77% 1895/2515 |
-1.39% 318/2655 |
| 2022 | -32.80% 1687/2207 |
-23.82% 1745/1919 |
-0.70% 1648/2016 |
-15.98% 1383/2113 |
5.73% 441/2208 |
| 2021 | 5.53% 543/1822 |
-10.88% 1121/1255 |
17.79% 179/1330 |
-8.13% 1105/1466 |
9.44% 120/1822 |
| 2020 | 30.94% 512/1250 |
0.72% 157/1028 |
27.07% 133/1067 |
0.77% 1038/1164 |
1.52% 1025/1184 |
| 2019 | 65.36% 41/1092 |
42.88% 34/754 |
-11.64% 770/804 |
18.51% 10/850 |
10.53% 123/918 |
| 2018 | -33.86% 557/834 |
- - |
- - |
- - |
-14.83% 595/691 |
| 2017 | 13.50% 263/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.24% 411/605 |
- - |
- - |
- - |
- - |
| 2015 | 44.31% 34/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华信息A VS. 长安沪深300非周期A(740101) |